Lifecore Biomedical Inc. Common Stock (LFCR)
Stock · NASDAQ · Health Care
$6.38as of 10/16/2026
Price chart
Active signals
LFCR Signal Track Record
How signals performed across all stocks →What LFCR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -4.6% | 39% | October 6, 2026 |
| Bollinger Band Breakout | 22 | -3.2% | 41% | September 28, 2026 |
| Bollinger Band Breakdown | 20 | -6.5% | 30% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 18 | +2.4% | 56% | February 9, 2026 |
| Any 20-session window (baseline) | -1.2% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 382
- Website
- www.lifecore.com/
Fundamentals
- 1-day range
- $6.39$6.43
- Market cap
- $181.55M
- P/E (trailing)
- —
- P/E (forward)
- -8.19
- EPS (trailing)
- $-1.31
- Dividend yield
- —
- Beta
- 0.99
- Avg. volume
- 310.5K
How Lifecore Biomedical Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Aug 7, 2025 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Lifecore Biomedical Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LFCRLifecore Biomedical Inc. Common Stock$6.38▼ 0.93%Market cap $181.55MP/E —$3.63$8.98
- CRBPCorbus Pharmaceuticals Holdings Inc. Common Stock$4.52▲ 4.39%Market cap $180.46MP/E —$4.37$20.56
- DERMJourney Medical Corporation Common Stock$4.97▼ 3.12%Market cap $179.80MP/E —$4.31$9.56
- ORMPOramed Pharmaceuticals Inc. Common Stock$4.07▼ 2.63%Market cap $178.87MP/E 0.98$2.09$5.47
- TNXPTonix Pharmaceuticals Holding Corp. Common Stock$6.04▼ 5.92%Market cap $185.71MP/E —$6.01$20.69
- KRROKorro Bio Inc. Common Stock$8.49▼ 8.81%Market cap $174.80MP/E —$5.2$55.89
- ARCTArcturus Therapeutics Holdings Inc. Common Stock$10.34▼ 8.25%Market cap $172.81MP/E —$5.5$24.17
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LFCR Lifecore Biomedical Inc. Common Stock | $181.55M | — | $6.38 | ▼ 0.93% | $3.63$8.98 |
| CRBP Corbus Pharmaceuticals Holdings Inc. Common Stock | $180.46M | — | $4.52 | ▲ 4.39% | $4.37$20.56 |
| DERM Journey Medical Corporation Common Stock | $179.80M | — | $4.97 | ▼ 3.12% | $4.31$9.56 |
| ORMP Oramed Pharmaceuticals Inc. Common Stock | $178.87M | 0.98 | $4.07 | ▼ 2.63% | $2.09$5.47 |
| TNXP Tonix Pharmaceuticals Holding Corp. Common Stock | $185.71M | — | $6.04 | ▼ 5.92% | $6.01$20.69 |
| KRRO Korro Bio Inc. Common Stock | $174.80M | — | $8.49 | ▼ 8.81% | $5.2$55.89 |
| ARCT Arcturus Therapeutics Holdings Inc. Common Stock | $172.81M | — | $10.34 | ▼ 8.25% | $5.5$24.17 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Lifecore Biomedical Q2 2026 Earnings Call Transcriptbenzinga · 10/8/2026
- Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools BankruptcyBenzinga · 10/2/2026
- Wynnefield Capital Discloses About 14.3% Stake In Lifecore Biomedical, Agrees To Vote In Favor Of Its Pending Merger, Per 13D FilingBenzinga · 9/29/2026
- Barrington Research Downgrades Lifecore Biomedical to Market PerformBenzinga · 9/29/2026
- Lifecore Biomedical: Bid Is UnderwhelmingSeekingAlpha · 9/29/2026
- Top stock movements in today's session.ChartMill · 9/28/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 9/28/2026
- Let's uncover which stocks are experiencing notable gaps during today's session.ChartMill · 9/28/2026
- William Blair Downgrades Lifecore Biomedical to Market PerformBenzinga · 9/28/2026
Insider Activity
Insider Actions →- Legion Partners, L.P. I · June 4, 2026 · Grant25.9K
- Paul Harold Johnson · June 4, 2026 · Grant25.9K
- Humberto Calheiros Antunes · June 4, 2026 · Grant25.9K
- Matthew E. Korenberg · June 4, 2026 · Grant25.9K
- Jason Aryeh · June 4, 2026 · Grant25.9K
- Joshua Schechter · June 4, 2026 · Grant25.9K
- Lovas Katrina Houde · June 4, 2026 · Grant25.9K
- Nelson Obus · June 4, 2026 · Grant25.9K
- Paul Josephs · May 20, 2026 · Tax Withholding40.4K @ $4.57
- Thomas D. Salus · April 14, 2026 · Tax Withholding24.6K @ $5.2
Institutional Ownership
March 31, 2026
- Total shares held
- 24.76M
- Total value held
- $110.33M
- Institutional holders
- 102
- Unknown4.70M
- Unknown4.46M
- Unknown3.54M
- Unknown2.16M
- Unknown1.88M
- Unknown1.29M
- Unknown827.5K
- Unknown815.1K
- Unknown764.7K
- Unknown642.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Lifecore Biomedical to be acquired by Webster Equity Partners
Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.
Lifecore Biomedical to be acquired by Webster Equity Partners. Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.